Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 95 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)		 HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NHzSeG1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVLmb2VmOi53LUG1JI5O NIfMenc4OiCq NVjMbolRcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NFzxT4QzPTd7MEmwOy=>
U2932  MYjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mof0Nk42NTF3IH7N MXW3NkBp MYXpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MUKyOVc6ODlyNx?=
OCI-LY7 M1rGV2NmdGxiVnnhZoltcXS7IFHzd4F6 MWmyMlUuOTVibl2= MmjmO|IhcA>? M2\k[Ylv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? Mn3ONlU4QTB7MEe=
Farage NVmwblM4S2WubDDWbYFjcWyrdImgRZN{[Xl? NXO3TmVuOi53LUG1JI5O NIfVV2E4OiCq NHXZXHhqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi M{D0TFI2PzlyOUC3
LY7/EBV NWG0VZhIS2WubDDWbYFjcWyrdImgRZN{[Xl? M{DzblIvPS1zNTDuUS=> MnTYO|IhcA>? MXjpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh M2rOXVI2PzlyOUC3
U2932/EBV NGL5TnBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGLvZoIzNjVvMUWgcm0> MXS3NkBp M{nPdolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NVK2Zph{OjV5OUC5NFc>
HCT116 M33MV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DnbVUuPTByMDDuUS=> MV2yOEBp M13CfmROW09? Mm\6bY5lfWOnczDj[YxtKGSnYYToJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy MorJNlU1QTJ3MUW=
ACH-2 M4KyVWZ2dmO2aX;uJGF{e2G7 NI\nNYIyNTlibl2= MVeyOEBp MoXNbY5lfWOnczDITXYuOSCHbo[g[ZhxemW|c3nvci=> NFXabIozPTF2OUS2Oy=>
MCF-10A NIrlVYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfaTWM2OD1yLkG3xtExNjBzIH7N NF;rSoIzPDl3NEi1Oi=>
MCF-7 NEDLSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFwMUFCtVAvOjBibl2= MXuyOFk2PDh3Nh?=
SK-BR-3 NFzNfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHviO29KSzVyPUGuNFDDuTBwM{Wgcm0> MofsNlQ6PTR6NU[=
MDA-MB-231 NEjoPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\EXY5RUUN3ME2wMlY5yrFyLkG0JI5O NGnqTJQzPDl3NEi1Oi=>
PC3 NX:5UGtRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTHTWM2OD1zLk[1xtExNjN3IH7N MUeyOFk2PDh3Nh?=
HCT116 NYXnZ4hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPibllKSzVyPUGuNFDDuTBwMECgcm0> MUGyOFk2PDh3Nh?=
HCT116-p21-/- NHPBfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFwMkdCtVAvOzdibl2= MXqyOFk2PDh3Nh?=
S1 NH\HWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\STWM2OD15Lk[3xtExNjJ7IH7N M2LzSVI1QTV2OEW2
SW620 MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XYNGlEPTB;MD65N:KyOC5{OTDuUS=> MorlNlQ6PTR6NU[=
LOX-IMVI M3rXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DwfGlEPTB;MD64O:KyOC5yMzDuUS=> Mnm2NlQ6PTR6NU[=
UACC-62 M4DDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH0SnlJUUN3ME2wMlU3yrFyLkG2JI5O NF7hfZgzPDl3NEi1Oi=>
MDA-MB-435 NX7ISIdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rTe2lEPTB;MD65NOKyOC5yNjDuUS=> M{PESFI1QTV2OEW2
SF-295 MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rUNGlEPTB;MD64POKyOC5zNTDuUS=> MkLQNlQ6PTR6NU[=
A549 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3D[4FKSzVyPUGuNlbDuTBwMkSgcm0> M3\2VlI1QTV2OEW2
H460 NHTPOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M335bmlEPTB;Mj61POKyOC56MDDuUS=> MkXzNlQ6PTR6NU[=
EKVX NGn3VpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFwM{RCtVAvOzRibl2= NF7WcZYzPDl3NEi1Oi=>
H146 NUnuUmVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPXTWM2OD1yLkKyxtExNjB5IH7N Ml[4NlQ6PTR6NU[=
H526 NX;zTmdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMUZCtVAvODNibl2= M4fMe|I1QTV2OEW2
HuT-78 M17w[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rkRmlEPTB;MT63N:KyOC52NDDuUS=> NHvoOY4zPDl3NEi1Oi=>
HA MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLZUocxNjZ{NT2xNI5O MWK0PEBp MUfpcoR2[2W|IHGgd4lodmmoaXPhcpRtgSC|dILvcodmeiCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBkdy22cnXheIVlKHerdHigZo9zfGW8b33pZi=> MYOyOFc4OTVzMB?=
MS-275 M{DzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDJNE43OjVvMUDuUS=> MlHWOFghcA>? NX3FXI1PcW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? MViyOFc4OTVzMB?=
CD4 T MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUm0PEBp M3HuO2VEPTB;ND61xtEyNjBibl2= NYLJVFBZOjR5MkK0OVQ>
CD4 T M4DGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrST|kyPDhiaB?= Mm\mR2M2OD1zMEhCtVEzPiCwTR?= NXjBUlRLOjR5MkK0OVQ>
CD4+ T NHm2U|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL0TYk6TUN3ME2zJI5O NG\G[YczPDR7NUGwOS=>
A549 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\BNVDjiJNzMEFCpI5O NFXRU4MzPC9|Nj:0PEBp M4OwPYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MmTyNlQ1QDV5OUm=
JJN3 NIDKRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSyOE81QCCq MY\FR|UxRDIkgJnuUVshPDkkgJno NGLDfIMzPDB|MEG1NC=>
OPM-2 M1\lPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLNNlQwPDhiaB?= NFzuW|dGSzVyc{2x5qCKdk19IES45qCKcA>? MUWyOFA{ODF3MB?=
RPMI-8226 M2DLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHMR4UzOjRxNEigbC=> NE\1cGxGSzVyc{2xMljjiImwTUugOFjjiImq MkT5NlQxOzBzNUC=
U266 M3jVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fGS|I1NzR6IHi= MXrFR|Uxez1zMPMAjY5OQyB2OPMAjYg> MmH5NlQxOzBzNUC=
CA46 M3PlcGFxd3C2b4Ppd{BCe3OjeR?= NVu4Z4ZiPiCq MYDpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? NFi1[GMzOzl4NkG2OC=>
DG75 NVPRNVg2SXCxcITvd4l{KEG|c3H5 MWW2JIg> NFrXdIxqdmS3Y3XzJI5wKGGyb4D0c5Nqew>? M3zPSFI{QTZ4MU[0
Ramos MWHBdI9xfG:|aYOgRZN{[Xl? MVi2JIg> NE\w[2hqdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> MUOyN|k3PjF4NB?=
ST486 MoXVRZBweHSxc3nzJGF{e2G7 MoD3OkBp Mn34bY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz M4fRb|I{QTZ4MU[0
HuT78 M3jqUmFxd3C2b4Ppd{BCe3OjeR?= NVfwbIxUOS9zMD:xNFAhdk1? MYm0PEBp NYrIPIN3cW6mdXPld{BieG:ydH;zbZMh[XRiMTDuUS=> MX2yN|U{Ojd|Mh?=
DpVp35 Mo\3RZBweHSxc3nzJGF{e2G7 M1j5SFEwOTBxMUCwJI5O MlvOOFghcA>? M3[3U4lv\HWlZYOgZox2dnRiYYDvdJRwe2m| MoPPNlM2OzJ5M{K=
DpVp50 M2Tab2Fxd3C2b4Ppd{BCe3OjeR?= NGPz[nIyNzFyL{GwNEBvVQ>? M2PUTFQ5KGh? MmfnbY5lfWOnczDicJVvfCCjcH;weI9{cXN? M{W4SlI{PTN{N{Oy
DpP75  MmfxRZBweHSxc3nzJGF{e2G7 NXjmR4ZMOS9zMD:xNFAhdk1? NWq4O4VxPDhiaB?= MmfXbY5lfWOnczDicJVvfCCjcH;weI9{cXN? NXS0Z3JTOjN3M{K3N|I>
SKOV-3 MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jiW|HjiJN{MH7N MnLzO|IhcA>? NYewUIloTE2VTx?= Mm\KdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> M{Tt[lI{ODFyM{S4
Brca1 WT MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTKSWtvOeLCk{Kwcm0> MoWxO|IhcA>? MlTYSG1UVw>? Ml\RdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NITN[IMzOzBzMEO0PC=>
Brca1 Null MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q0VlHjiJN{MH7N M{nYUFczKGh? MlXhSG1UVw>? MY\y[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> Mn\WNlMxOTB|NEi=
OVCAR-8  M1W3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS4coYy6oDVMkDuUS=> MlfVO|IhcA>? NEj5ZWVFVVOR NXTMc3dZemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MWCyN|AyODN2OB?=
NCI/ADR-RES MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D6[VHjiJN{MH7N MUS3NkBp M3L6RmROW09? MXTy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> NY\RNWFiOjNyMUCzOFg>
HCT116 Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;vU5lbPSCwTT21NEDPxE1? MnKxNlQhcA>? NXjoeW9NTE2VTx?= NVnmSXcycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NWq5fHJMOjJ7MkS5OVg>
RKO MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfNZ5M2KG6PLUWwJO69VQ>? NVr0U5A4OjRiaB?= M{jlXGROW09? MnL3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> M4O0blIzQTJ2OUW4
CO115 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK4XI02KG6PLUWwJO69VQ>? MlPTNlQhcA>? NV7YbYptTE2VTx?= M3\H[olvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NYXxeJlDOjJ7MkS5OVg>
HFS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L2cFUhdk1? NGH4PJkzPC92OD:3NkBp MnzmbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> NUjtbWR5OjJzME[yPFI>
LNCaP M3;PcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLFUlB1PSCwTR?= NGPQcpgzPC92OD:3NkBp NXHvXldbcW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? NWHic5hzOjJzME[yPFI>
A549 M3fCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYq1JI5O M17jUlI1NzR6L{eyJIg> MmDrbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> MXWyNlExPjJ6Mh?=
697  MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHFXlN1UUN3MPMAjV3jiIl{LkZCpI5O M3\SXlIyPTN6MkG2
697-R MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTiSYd[UUN3MPMAjV3jiIl6LkdCpI5OyqB? MnfoNlE2Ozh{MU[=
HUT78 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\STWM2OD1zIH7N M1nQcVIyOTl6NUS1
THJ-16T NI\SSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHhTI4yKG6P NIi4d2EzPCCq NVOzRYpTcW6qaXLpeJMh[2WubDDndo94fGh? M1;TUVIxQDFyNU[4
HCT116 MUnGeY5kfGmxbjDBd5NigQ>? NXjLeYlNOjBibl2= MWe4JIg> MoTTcY9lfWyjdHXzJJRz[W6|Y4LpdJQhdGW4ZXzzJIZweiCqdX7kdoVleyCxZjDn[Y5meyCrbjDlbZRp\XJiZHny[YN1cW:w NGDDSHQzODd|OUS1OC=>
B104  MUjGeY5kfGmxbjDBd5NigQ>? M3vCdVIhdk1? NGDLb|IzPC92OD:3NkBp NGfuRXhqdmO{ZXHz[ZMhfGinIIP1doZi[2ViZYjwdoV{e2mxbjDv[kBETDJywrC= MVWyNFY5PjVyNR?=
HL-60  MULDfZRwfG:6aXPpeJkhSXO|YYm= MlnwNU02ODBibl2= NXj0[Gg6OjRiaB?= NH7SRVlqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MVmyNFYzPDF4Mx?=
HP100 Mn63R5l1d3SxeHnjbZR6KEG|c3H5 Mmm1NU02ODBibl2= NXr6XJk2OjRiaB?= MWHpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh M3uybVIxPjJ2MU[z
HL-60  NW\2PIx1TnWwY4Tpc44hSXO|YYm= NEHzTnYyOCCwTR?= NVfrT5dTPC94L{G2JIg> NUjofI86cW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo M4e2W|IxPjJ2MU[z
HP100 M2O0TGZ2dmO2aX;uJGF{e2G7 MnWwNVAhdk1? M3[xTlQwPi9zNjDo MlvObY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq NUS0[HBOOjB4MkSxOlM>
HL-60  NG\rTHdHfW6ldHnvckBCe3OjeR?= NEnrSZAyOC13MECgcm0> MWe0JIg> NVfWcJB[\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg NITacW0zODZ{NEG2Ny=>
HP100 M1r6N2Z2dmO2aX;uJGF{e2G7 MV6xNE02ODBibl2= MmLCOEBp NYLTVZVm\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg MW[yNFYzPDF4Mx?=
11z NIXmc2RMcW6jc3WgRZN{[Xl? M3PWclMuOTByIH7N MYDy[YR2[2W|IFjERWMh\W68eX3heIlkKGGldHn2bZR6KCiLQ{WwxsA:KDZwNTFCtUAxNjZibn3vcE9NMQ>? MmPhNlA3ODVzNES=
SKOV-3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jtRVQwQC9zNjDuUS=> NGf6d3g1QCCq MVXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NXXt[JBrOjB2MES1OlQ>
OVCAR-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XTWVQwQC9zNjDuUS=> NIH2WXo1QCCq MkXPbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NWXoRXljOjB2MES1OlQ>
HBL-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTMN2szNTFyIH7N NEO0PFUzPCCq NIjSVnRKSzVyPUSuN{BvVQ>? M3K1e|IxODZ6MEiw
Jeko-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVqyMVUxKG6P M17OVVI1KGh? NH;3eIRKSzVyPUGxJI5O NWrubYZ2OjByNkiwPFA>
Granta-519 NFK5XGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;rOU01OCCwTR?= M1j1[|I1KGh? M4PNNGlEPTB;NUiuOUBvVQ>? M2H1TVIxODZ6MEiw
L1236 NUTFU4dvS3m2b4TvfIlkcXS7IFHzd4F6 M4nJWFEhdk1vMUCwJO69VQ>? MmS1OFghcA>? MWHFR|UxRTBwMEeg{txO MmWyNVkzOzN2N{C=
L428 MWPDfZRwfG:6aXPpeJkhSXO|YYm= MYqxJI5ONTFyMDFOwG0> MWm0PEBp NU[4dYtuTUN3ME2wMlQ{KM7:TR?= MlXsNVkzOzN2N{C=
KM-H2 NWDScG1lS3m2b4TvfIlkcXS7IFHzd4F6 MnTkNUBvVS1zMECg{txO Mnn1OFghcA>? MVTFR|UxRTBwNUig{txO MmTsNVkzOzN2N{C=
L540Cy NXTBdoNGS3m2b4TvfIlkcXS7IFHzd4F6 NGmxNZEyKG6PLUGwNEDPxE1? NHzGWVA1QCCq MoT2SWM2OD1yLkG2JO69VQ>? NETuZ|QyQTJ|M{S3NC=>
G401 NH[3V3pHfW6ldHnvckBCe3OjeR?= MYixNEBvVQ>? NYHM[YJQOjRxNEivO|IhcA>? NFjDTIdFVVOR NHjwN25qdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> M130VFE6OjJzNUi2
STM91-01 M3Tme2Z2dmO2aX;uJGF{e2G7 MXexNEBvVQ>? MnTnNlQwPDhxN{KgbC=> MoeySG1UVw>? NFTuOVhqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> M{D4[lE6OjJzNUi2
SJSC  MVjGeY5kfGmxbjDBd5NigQ>? NHLrWpcyOCCwTR?= M{X6PFI1NzR6L{eyJIg> NVzUPGdbTE2VTx?= NITXTJJqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> NHLyNW4yQTJ{MUW4Oi=>
BT16  NGnWeVNHfW6ldHnvckBCe3OjeR?= NFvoNnIyOCCwTR?= MYOyOE81QC95MjDo Mn3qSG1UVw>? MneybY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u MXmxPVIzOTV6Nh?=
NCI-H1299 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET4b4hKSzVyPUSuOuKyOC5{IH7nM41t M{HqVlE6OTd7OEmw
NCI-2882 M2H6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\JepRKSzVyPUGuOuKyOC5yNDDu[{9udA>? NGiwWVEyQTF5OUi5NC=>
HCC95 M1jGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJwNdMxNE4xPSCwZz;tcC=> MXSxPVE4QTh7MB?=
NCI-H23 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\0WWlEPTB;Mj65xtExNjJibnevcYw> NGDMPXUyQTF5OUi5NC=>
NCI-H157 M{Huc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTFwNtMxNE4xOiCwZz;tcC=> NYTtdYF{OTlzN{m4PVA>
NCI-H460 NHrwNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn4bo5KSzVyPUKuNeKyOC5yNzDu[{9udA>? Moe1NVkyPzl6OUC=
NCI-H1975 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofrTWM2OD1zLkRCtVAvODRibnevcYw> MkXPNVkyPzl6OUC=
NCI-H820 NFHs[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDRVIpPUUN3ME2yMlTDuTBwMTDu[{9udA>? MXexPVE4QTh7MB?=
NCI-H1650 NGqzSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HTVGlEPTB;ND65xtExNjNibnevcYw> NVjXcY1tOTlzN{m4PVA>
DTC1 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrrZZdKSzVyPUCuOVEhdk1? MY[xPFU3PjJ2Nh?=
KAO M3TNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvISpRKSzVyPUCuPVEhdk1? MWOxPFU3PjJ2Nh?=
SU-CCS-1 MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfZR4E{UUN3ME2wMlg6KG6P NHvtXngyQDV4NkK0Oi=>
SYO-1 M1zuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7xW|RRUUN3ME2wMlY4KG6P MkD3NVg2PjZ{NE[=
FUJI MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf3W5lKSzVyPUGuN|Ehdk1? NFjRPYoyQDV4NkK0Oi=>
SKNMC NF;yNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFwMUegcm0> M1jqSlE5PTZ4MkS2
402-91 NEDVZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHKwVmZKSzVyPUGuNlYhdk1? NGHNTIcyQDV4NkK0Oi=>
1765-92 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwN{egcm0> NGXUe2syQDV4NkK0Oi=>
JN-DSRCT-1 MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfkZW9KSzVyPUGuNlUhdk1? MU[xPFU3PjJ2Nh?=
NMS-2PC M3nNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPrTWM2OD1yLkixJI5O NUexS2UxOTh3Nk[yOFY>
HL60 NGX3e|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj4Z3ZwUUN3ME2xMlg3KG6P NVq2NY5GOTh3Nk[yOFY>
A549 NX3wcGRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTNwMkSgcm0> MmHKNVg2PjZ{NE[=
SW480 NHPBbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW3ZlZKSzVyPUKuOlkhdk1? NYPlS|RnOTh3Nk[yOFY>
MCF7 MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTNwNUWgcm0> NVnEb3VWOTh3Nk[yOFY>
PC-3 NHrGSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDGVlVKUUN3ME2yMlUyKG6P MVmxPFU3PjJ2Nh?=
MMRU NET4TVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NECxTGVKSzVyPUKuOVchdk1? MXGxPFU3PjJ2Nh?=
Hs68 NVfOZmFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf2fmhuUUN3ME2+NVAhdk1? MlzQNVg2PjZ{NE[=
hMSC-001F NU\mUWJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDXTWM2OD1-MUCgcm0> NXTxU3BQOTh3Nk[yOFY>

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p21 / Cyclin D1; 

PubMed: 19682393     


NIH 3T3 cells stably expressing the indicated proteins were treated with DMSO (Vehicle) or the indicated concentration of romidepsin for 24 h. Cell lysates were analyzed by western blotting with antibodies to cyclin D1, p21 and β-actin (loading control). Data shown are representative of at least two independent experiments.

AcH3(K9) / Ac-α-Tubulin(K40) / Ac-NFκB2(K310) p65 / 3MeH3(K27); 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

HDAC3 / HDAC4 / HDAC6 / HDAC2; 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

γH2AX / PARP1 / Cleaved caspase3 / BAK / p21(waf1/cip1) / XIAP; 

PubMed: 26473529     


Western blot analysis of proteins involved in DNA-damage response and apoptosis. Established cell lines were exposed to different concentrations of romidepsin (Rom) for 48 h and total cell extracts were analyzed.

Cyclin E1 / BRCA1 / E2F1 / Cleaved PARP / H3Ac; 

PubMed: 27444036     


Western blot analysis of the effects of panobinostat (25 nM), vorinostat (5 µM) and romidepsin (10 nM) on expression of cyclin E1, E2F1, BRCA1, cleaved PARP and acetylated histone H3 in OVCAR-3 cells. Actin and histone H3 were loading controls. 

pAKT(S473) / pAKT(T308) / AKT; 

PubMed: 25492515     


Western blot analysis of phosphorylated AKT in PC3 cells. Cells were treated for 3 h with various concentrations of FK228. 

19682393 26473529 27444036 25492515
Growth inhibition assay
Cell viability; 

PubMed: 27444036     


Concentration-dependent effects of panobinostat and vorinostat in SRB viability assays in OVCAR-3 cells (72 h). Values are mean+SE of 3 independent experiments. 

27444036
Immunofluorescence
SS18/TLE1; 

PubMed: 27120803     


A significant decrease in detectable PLA signal following HDAC inhibition in SYO-1 cells.

Cleaved caspase-3; 

PubMed: 22531354     


TDP-B activates cleaved caspase-3 by immunofluorescence. Representative immunofluorescence staining for cleaved caspase 3 (green) in SKOV-3 ovarian cancer cells treated with 10 nM FK228, TDP-A or TDP-B after 24 h of exposure. The nuclei are stained with DAPI (blue).

27120803 22531354
In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]
- Collapse

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]
- Collapse
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]
- Collapse
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2
CAS No. 128517-07-7
Storage powder
in solvent
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03770000 Recruiting Drug: Tenalisib|Drug: Romidepsin T Cell Lymphoma Rhizen Pharmaceuticals SA March 12 2019 Phase 1|Phase 2
NCT02616965 Recruiting Drug: Romidepsin|Drug: Brentuximab vedotin Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics Inc.|Celgene Corporation February 22 2017 Phase 1
NCT02616874 Completed Drug: MVA.HIVconsv vaccine|Drug: Romidepsin HIV IrsiCaixa|Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA|Hospital Clinic of Barcelona|Hospital de Sant Pau|HIVACAT|University of Oxford|BCN Checkpoint February 2016 Phase 1
NCT03141203 Recruiting Drug: Romidepsin|Drug: Carfilzomib Peripheral T Cell Lymphoma University of Birmingham|Bloodwise|Celgene|Amgen July 13 2015 Phase 1|Phase 2
NCT02393794 Recruiting Drug: Romidepsin|Drug: Cisplatin|Drug: Nivolumab Triple-Negative Breast Cancer|Breast Cancer Priyanka Sharma|Celgene Corporation|Bristol-Myers Squibb|University of Kansas Medical Center July 17 2015 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

  • LMK-235 New

    LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.

  • CAY10603 New

    CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.

  • Domatinostat (4SC-202,Domatinostat) New

    4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.

  • Panobinostat (LBH589)

    Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

  • Entinostat (MS-275)

    Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

  • Trichostatin A (TSA)

    Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

  • RGFP966

    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.

  • Tubastatin A

    Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).

  • Mocetinostat (MGCD0103)

    Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID